LASE Innovation

What LASE Innovation does

The available input contains no source-attributed company records, source identifiers, dates, figures, or direct statements about LASE Innovation. Consequently, its products, technology, customers, locations, business model, funding, partnerships, hiring, and research activity cannot be verified or described under the required attribution rules. The evidence is therefore insufficient to support an investment-grade company description, and no company facts should be inferred beyond this documentation gap.

Name

LASE Innovation

Legal name

LASE Innovation Inc.

Website

https://laseinnovation.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

No source-attributed company information was provided in the available input, so the company's functions, technology, products, customer segments, business model, operating locations, and competitive position cannot be described reliably here.

Ownership category

akta.pro rank

NAICS

Analytical Laboratory Instrument Manufacturing (334516), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Laboratory Analytical Instruments (3826), Services-Medical Laboratories (8071)

akta.pro primary industry

Microscopy, Imaging & Flow Cytometry Instruments (HLAGAIAE)

akta.pro secondary industries

Flow Cytometry & Cellular Analysis Diagnostics (HLAHAAAF), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

Keywords

• Single-cell analysis
• Flow cytometry services
• Optical cell barcoding
• T cell therapy analytics
• Laser particle technology

Headquarters

HQ city

Woburn

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Revenue model

1. Time-lapse Flow Cytometry Services: The company offers Time-lapse Flow Cytometry as a commercial service from their Waltham, MA facility. Customers submit project proposals, receive quotes, and issue POs for service-based engagement. They partner with Talon Biomarkers to exclusively offer these services.
2. LASE Cytometer Instrument Sales: Planned commercial launch of the LASE Cytometer and LP tagging technology for release in early 2026, representing future hardware product revenue.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

LASE Innovation provides Time-lapse and Multi-pass Flow Cytometry services built on its patented LP Optical Cell Barcoding platform, which uses SWIR-emitting laser particles to individually barcode and longitudinally track millions of cells across flow cytometry, imaging, microscopy, in vivo, and RNA-sequencing platforms. The Time-lapse TITAN Assay Service, launched in August 2025 with Talon Biomarkers, is the first commercially available flow cytometry-based method to measure kinetics of human T cell activation at single-cell resolution. A proprietary LASE Cytometer instrument is in late-stage development for 2026 release.

Product overview

LASE Innovation offers a platform centered on its patented LP (Laser Particle) Cell Barcoding technology, which provides massively multiplexed optical cell barcoding using light-emitting nano-to-micron sized particles with narrowband SWIR emission tuned to over 1000 wavelengths. The platform enables single-cell identification and tracking across multiple single-cell and omics platforms including flow cytometry, imaging, microscopy, in vivo, and RNA-sequencing. The flagship instrument under development is the LASE Cytometer, integrated with LP-enabled SWIR detection optics. Commercial offerings include the Time-lapse TITAN Assay Service (offered in partnership with Talon Biomarkers) and Multi-pass Flow Cytometry services, both running at LASE's Waltham, MA BSL-2 facility. The Time-lapse Flow Cytometry application tracks the same cells over time (up to 4 days) providing longitudinal single-cell data, while Multi-pass Flow Cytometry enables high-marker panels (20–30+ markers) through sequential barcoded runs.

Differentiator

Problem solved

Functional benefit

Brands

• LP Cell Barcoding: Massively multiplexed optical cell barcoding platform using laser particles (LP) for single-cell identification and tracking across multiple platforms
• Time-lapse Flow
• Multi-pass Flow
• LASE Cytometer
• Time-lapse TITAN Assay

Quantifiable outcome

• Track up to 7 dynamic biomarkers over 4 days at single-cell resolution
• +1 more outcomes

Named customers3 records

Segments3 records

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Partnerships

One partnership is on record.

• Talon BiomarkerscoreStrategic or Co-development Partner · 8 January 2024Strategic service provider partnership where Talon Biomarkers exclusively offers LASE's Multi-pass and Time-lapse flow cytometry services to their biopharmaceutical customers. Talon Biomarkers is a contract research organization focused on high content immune analysis for biomarker discovery, led by Dr. Pratip K. Chattopadhyay, an internationally recognized leader in immune monitoring and flow cytometry. The partnership pairs LASE's LP Cell Barcoding platform with Talon's expertise in development and application of flow cytometry.

Scale indicators1 record

Direct peers

• Cytek Biosciences: Cytek develops and commercializes full-spectrum flow cytometry instruments (Aurora, Northern Lights) used by pharma and academic immunology labs. Directly comparable to LASE because it sells bench-top flow cytometers to the same immuno-oncology and cell therapy customers LASE serves, and competes for the same flow cytometry capital equipment budget.
• 10x Genomics: 10x Genomics offers Chromium single-cell platforms (including feature barcoding for multi-omics) that compete with LASE's single-cell tracking capability. Overlaps with LASE in single-cell analysis, multi-omics, and biopharma customers developing cell therapies, though 10x's core modality is sequencing-based rather than flow cytometry.
• Standard BioTools (formerly Fluidigm): Standard BioTools sells the Hyperion imaging mass cytometry and mass cytometry (Helios) systems for high-dimensional single-cell analysis. Comparable to LASE in targeting pharma/biotech immuno-oncology researchers who need high-parameter single-cell data and selling instruments into the same lab budgets.

Broad incumbents

• BD Biosciences (Becton Dickinson): BD is the dominant incumbent in flow cytometry (BD FACSCelesta, BD FACSymphony, BD CellView) and the largest installed-base competitor for any new flow cytometry platform. Comparable as the broad incumbent whose existing customer relationships and instrument footprint LASE must displace.
• Beckman Coulter Life Sciences: Beckman Coulter sells the CytoFLEX and Navios flow cytometry platforms widely used in clinical research and pharma immunology labs. Comparable as an incumbent offering standardized flow instruments to the same T cell and immune-monitoring research customers LASE targets.
• Bio-Rad Laboratories: Bio-Rad offers the ZE5 cell analyzer and other flow cytometry instruments plus the StarBright and other reagent lines used in immunology research. Comparable as a broad life-science tools incumbent with flow cytometry products competing for the same pharma/academic budgets.
• Thermo Fisher Scientific (Life Technologies): Thermo Fisher sells the Attune NxT flow cytometer and a deep catalog of flow cytometry antibodies and reagents. Comparable as a broad incumbent serving the same biopharma and academic immunology customers with both instruments and consumables.
• Luminex (DiaSorin/Merck KGaA): Luminex (acquired by DiaSorin) provides the Amnis imaging flow cytometry and other multiplexed cellular analysis platforms used in immunology research. Comparable as an established flow/imaging flow vendor serving the same pharma/biotech immuno-oncology customers, and as a former employer of LASE's CCO.

Emerging players

• Mission Bio: Mission Bio sells the Tapestri single-cell multi-omics platform focused on genomics/proteomics at single-cell resolution. Comparable as an emerging single-cell analysis vendor targeting pharma cell therapy developers and competing for the same translational research budgets.
• IsoPlexis (now part of standard process; ex- entity): IsoPlexis provided single-cell functional proteomics platforms (IsoLight) used by cell therapy developers for potency assessment. Comparable as an emerging single-cell tools player serving CAR-T and T cell therapy development workflows similar to LASE's Time-lapse TITAN Assay customers.

Market position

Strengths5 records

Weaknesses5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/lase-innovation

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LASE Innovation